- Book
- February 2024
- 928 Pages
- Book
- December 2022
- 464 Pages
- Book
- December 2021
- 624 Pages
- Book
- April 2021
- 6032 Pages
€3984EUR$4,640USD£3,333GBP
- Book
- October 2020
- 384 Pages
- Book
- November 2019
- 440 Pages
- Book
- November 2019
- 368 Pages
- Book
- October 2019
- 472 Pages
- Book
- June 2019
- 496 Pages
- Book
- June 2019
- 304 Pages
- Book
- May 2018
- 1064 Pages
- Book
- January 2016
- 472 Pages
- Book
- August 2013
- 386 Pages
- Book
- February 2013
- 512 Pages
- Book
- March 2012
- 450 Pages
- Book
- September 2010
- 484 Pages
- Book
- September 2010
- 984 Pages
- Book
- March 2010
- 784 Pages
- Book
- September 2009
- 306 Pages

The Protein Drugs market is a subset of the larger Drug Discovery industry. It focuses on the development of drugs that are based on proteins, such as monoclonal antibodies, cytokines, and growth factors. These drugs are used to treat a variety of diseases, including cancer, autoimmune disorders, and infectious diseases. Protein drugs are typically developed through recombinant DNA technology, which involves the manipulation of genetic material to create a desired protein.
The Protein Drugs market is highly competitive, with many companies vying for a share of the market. Companies in the market include AbbVie, Amgen, AstraZeneca, Biogen, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. These companies are engaged in research and development of new protein drugs, as well as the marketing and distribution of existing drugs. Show Less Read more